C&G Editor in Chief, Erin Harris

  1. Navigating The Cell & Gene Talent Crunch 6/14/2021

    Michael Mehler, Sr. Clinical Development Manager at GSK and Cell & Gene Editorial Advisory Board member joins Matt Pillar’s Business of Biotech podcast to discuss hiring and retaining cell and gene professionals.

  2. AAV & Lentivirus Gene Therapies With Sio Gene Therapeutics' Dr. Pavan Cheruvu 6/7/2021

    I had the opportunity to guest host on Matt Pillar’s Business of Biotech podcast recently when Matt and I chatted Sio Gene Therapies CEO Pavan Cheruvu, M.D. We discuss Dr. Cheruvu's formative years and inspiration, and more. 

  3. 2021 WMIF Fireside Chat With Thermo Fisher Scientific CEO: Partnering Across The Cell & Gene Therapy Spectrum 5/25/2021

    During Mass Brigham General’s 2021 World Medical Innovation Forum (WMIF), I had the opportunity to participate in a virtual Fireside Chat titled “Partnering Across the Cell & Gene Therapy Spectrum” with Marc Casper, CEO of Thermo Fischer Scientific. 

  4. BridgeBio On Long-Term Strategy, ASCGT Presentation 5/25/2021

    Eric David, M.D., J.D., CEO at BridgeBio Gene Therapy discusses the company’s long-term strategy as well as manufacturing expectations for BBP-631. 

  5. Ultragenyx Explains Advancements In Manufacturing Scalability For Gene Therapy 5/19/2021

    Sam Wadsworth, Chief Scientific Officer at Ultragenyx Gene Therapy, shares details about the company’s HeLa gene therapy platform and how the company’s AAV-based therapies differ from others like it.

  6. A Recap Of Tessa Therapeutics’ Data On CD30+ Lymphomas Presented At The ASCGT 24th Annual Meeting 5/18/2021

    Tessa Therapeutics’ President and CEO Jeffrey H. Buchalter explains positive, topline data from Its on-going Phase 1 trial in patients with relapsed or refractory CD30-Positive Lymphoma.

  7. A Look at Repeat Expansion Disorders 4/29/2021

    Irina Antonijevic, M.D., Ph.D., Chief Medical Officer and Nessan Bermingham, Ph.D., CEO, President, and Founder atTriplet Therapeutics explain the pre-clinical data as well as the company’s equity pledge that will help to benefit patients of the RED community. 

  8. Regulatory Requirements Featuring bluebird bio 4/26/2021

    Just recently, I had the chance to sit down with Matt Pillar and bluebird bio’s VP Regulatory Operations and Compliance, Scott Cleve, for a candid discussion on the regulatory trends shaping the advance of bluebird’s pipeline of gene therapies for the treatment of serious, life-altering diseases including Cerebral Adrenoleukodystrophy, Multiple Myeloma, Transfusion-Dependent β-Thalassemia, and Sickle Cell Disease.

  9. The Center For Breakthrough Medicines’ Newest Leaders Talk Advanced Therapy Development, Manufacturing 4/1/2021

    I had the opportunity to connect with four of The Center for Breakthrough Medicines' newest leaders about their respective roles, the future of manufacturing, and much more. 

  10. Inside Repertoire Immune Medicines’ T Cell Recognition Of SARS-CoV-2 4/1/2021

    Anthony Coyle, Ph.D., President, Research and Development at Repertoire Immune Medicines explains the company's DECODE platform and the role it played in the T cell recognition of SARS-CoV-2.